In our in vitro assay, we showed that soluble human recombinant CD47 Fc and CD200 Fc could reduce IL-6 release but did not suppress IL1-β or IL-17 production, in living cortical brain slices from patients with FCD IIb and TSC. The gene discussed is IL1B; the disease is tuberous sclerosis.